Pharmaceutical Giant Acquires Nimbus Health

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com



FOR PUBLIC RELEASE
NZX Limited
Wellington

Friday, February 4, 2022


Pharmaceutical Giant Acquires German Distributor Nimbus Health

Rua Bioscience (NZX: RUA) is pleased to share the news that multi-national pharmaceutical
company Dr Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC:
DRREDDY) today announced it has entered into a definitive agreement to acquire Nimbus Health
GmbH (Nimbus Health). Rua Bioscience was the first New Zealand company to announce a
binding export agreement with the reputable distributor in Germany and is Nimbus Health's
exclusive New Zealand supplier of medicinal cannabis products.

Rua Bioscience CEO, Rob Mitchell, says this is exciting news. Nimbus Health will become a wholly-
owned subsidiary of Dr Reddy’s.

"This is another example of the international pharmaceutical industry's growing interest in the
burgeoning medicinal cannabis industry, following Jazz Pharmaceuticals USD7.2bn acquisition of
GW pharmaceuticals in early 2021. The acquisition will allow Dr Reddy's to build on Nimbus
Health's strengths and introduce medical cannabis-based medicines as a promising treatment
option for patients.

“Nimbus Health will expand its operations through access to Dr Reddy's significant EU
pharmaceutical sales and marketing capabilities. For Rua, this will ultimately lead to greater
reach for our products in the German market and potentially beyond,” Rob says.

Dr Alessandro Rossoni, Co-Founder and Managing Director of Nimbus Health, says that the team
is excited that Dr Reddy's acknowledged the potential of Nimbus in the medical cannabis market.

"Dr Reddy's commitment sets a significant milestone for further developing medical cannabinoid-
based medicines and unlocking new possibilities to benefit patients. We are very confident that
being part of Dr Reddy's will help us strongly take our operations to the next level and further
increase our impact in this quickly developing market."

Rua expects to export dried flower and oil products to Germany under its distribution agreement
with Nimbus Health from H2, 2022.


Ends.

About Nimbus Health GmbH
Nimbus Health is a fully licensed pharmaceutical wholesaler and manufacturer from Germany
with its warehouse facilities and an independent sales force to promote medical cannabis-based
products to pharmacists. Its mission is to supply seriously ill patients with the highest grade
medical cannabis products from reliable sources consistently and sustainably.




MARKET ANNOUNCEMENT

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com



About Dr Reddy's
Dr Reddy's is an integrated pharmaceutical company committed to providing affordable and
innovative medicines for healthier lives. Through its businesses, Dr Reddy's offers a portfolio of
products and services, including APIs, custom pharmaceutical services, generics, biosimilars and
differentiated formulations. Its major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's operates
in markets across the globe. Its major markets include – USA, India, Russia & CIS countries, and
Europe. For more information, log on to: www.drreddys.com

For more information, please contact:
Kerry Donovan
Communications Manager Rua Bioscience
Email: kerry.donovan@ruabio.com
Phone: 021 128 7689